Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010-2018)

By sjmartinez • February 22, 2023

Bourassa-Blanchette S, Biesheuvel MM, Lam JC, Kipp A, Church D, Carson J, Dalton B, Parkins MD, Barkema HW, Gregson DB. Incidence, susceptibility and outcomes of candidemia in adults living in Calgary, Alberta, Canada (2010-2018). BMC Infect Dis. 2023 Feb 20;23(1):100. doi: 10.1186/s12879-023-08050-0. PMID: 36803357; PMCID: PMC9940426.

Tags: Antifungal susceptibility, Candida, Fungemia, Incidence, Infectious Diseases, mortality, Publications

Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis

Gebremariam T, Gu Y, Patterson H, Youssef E, Alkhazraji S, Elsayed T, Wiederhold NP, Ibrahim AS. Efficacy assessments of SF001, a next-generation polyene antifungal, in[...]

Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia

Dao KT, D'Assumpcao C, Sharma R, Singh C, Kuran R, Heidari A. Clinical Telavancin Failure in Persistent Methicillin-Resistant Staphylococcus aureus Bacteremia. Cureus. 2025 Feb 24;17(2):e79588.[...]

Implementation of a seamless phase 2/3 study design in the setting of an emergent infectious disease pandemic: Lessons learned from the ACTIV-2 platform COVID-19 treatment trial

Giganti MJ, Chew KW, Moser C, Eron JJ, Pinilla M, Li JZ, Ritz J, Javan AC, Wohl DA, Daar ES, Currier JS, Smith DM, Hughes[...]